Baseline characteristics for ticagrelor-treated and clopidogrel-treated patients stratified by estimated glomerular filtration rate (eGFR)
| eGFR (mL/min/1.73 m2) | >60 | P value | 30–60 | P value | <30 | P value | |||
| Ticagrelor, N=9538 | Clopidogrel, N=24 130 | Ticagrelor, N=1986 | Clopidogrel, N=7817 | Ticagrelor, N=210 | Clopidogrel, N=1525 | ||||
| Demographics | |||||||||
| Age, median (IQR) | 65.0 (57.0–72.0) | 67.0 (59.0–76.0) | <0.001 | 77.0 (70.0–82.0) | 81.0 (74.0–86.0) | <0.001 | 78.0 (69.0–84.0) | 80.0 (72.0–86.0) | 0.013 |
| Sex (male), n (%) | 7080 (74.2) | 16 657 (69.0) | <0.001 | 1169 (58.9) | 4269 (54.6) | <0.001 | 118 (56.2) | 851 (55.8) | 0.94 |
| Presentation | |||||||||
| STEMI, n (%) | 4462 (46.8) | 7828 (32.3) | <0.001 | 819 (41.2) | 2092 (26.5) | <0.001 | 76 (36.2) | 341 (22.2) | <0.001 |
| NSTEMI, n (%) | 5076 (53.2) | 16 302 (67.7) | <0.001 | 1167 (58.8) | 5725 (73.5) | <0.001 | 134 (63.8) | 1184 (77.8) | <0.001 |
| Killip class >1 on admission, n (%) | 450 (4.7) | 1749 (7.3) | <0.001 | 236 (11.9) | 1372 (17.6) | <0.001 | 46 (12.9) | 375 (24.6) | 0.38 |
| AF on admission, n (%) | 208 (2.2) | 1113 (4.6) | <0.001 | 118 (6.0) | 928 (12.0) | <0.001 | 16 (7.8) | 223 (14.7) | 0.014 |
| Cardiovascular risk factors | |||||||||
| Diabetes, n (%) | 1812 (19.0) | 4913 (20.4) | 0.005 | 584 (29.4) | 2436 (31.2) | 0.13 | 109 (51.9) | 690 (45.2) | 0.08 |
| Hypertension, n (%) | 4394 (46.3) | 11 926 (49.8) | <0.001 | 1458 (73.7) | 5799 (74.7) | 0.37 | 187 (89.5) | 1307 (86.0) | 0.20 |
| Current smoker, n (%) | 2789 (30.0) | 6209 (27.0) | <0.001 | 283 (15.1) | 806 (11.5) | <0.001 | 27 (13.8) | 181 (13.7) | 1.00 |
| Previous cardiovascular disease | |||||||||
| MI, n (%) | 1470 (15.5) | 5259 (21.9) | <0.001 | 515 (26.2) | 3098 (39.9) | <0.001 | 89 (43.0) | 751 (49.7) | 0.08 |
| PCI, n (%) | 1147 (12.1) | 3631 (15.1) | <0.001 | 352 (17.9) | 1592 (20.7) | 0.007 | 47 (22.6) | 364 (24.4) | 0.60 |
| CABG, n (%) | 435 (4.6) | 1603 (6.7) | <0.001 | 191 (9.6) | 1002 (12.9) | <0.001 | 28 (13.4) | 227 (15.0) | 0.60 |
| CHF, n (%) | 452 (4.7) | 1923 (8.0) | <0.001 | 283 (14.2) | 1966 (25.2) | <0.001 | 75 (35.7) | 617 (40.5) | 0.20 |
| PVD, n (%) | 242 (2.5) | 925 (3.8) | <0.001 | 157 (7.9) | 713 (9.1) | 0.093 | 37 (17.6) | 285 (18.7) | 0.78 |
| Ischaemic stroke, n (%) | 402 (4.2) | 1678 (7.0) | <0.001 | 268 (13.6) | 1280 (16.4) | <0.001 | 39 (18.6) | 333 (21.8) | 0.32 |
| Previous other disease | |||||||||
| Intracranial bleeding, n (%) | 78 (0.8) | 266 (1.1) | 0.019 | 34 (1.7) | 129 (1.7) | 0.84 | 3 (1.4) | 27 (1.8) | 1.00 |
| Dementia, n (%) | 23 (0.2) | 102 (0.4) | 0.013 | 12 (0.6) | 98 (1.3) | 0.012 | 2 (1.0) | 12 (0.8) | 0.68 |
| COPD, n (%) | 475 (5.0) | 1560 (6.5) | <0.001 | 140 (7.0) | 750 (9.6) | <0.001 | 29 (13.8) | 175 (11.5) | 0.36 |
| Cancer within last 3 years, n (%) | 166 (1.7) | 628 (2.6) | <0.001 | 73 (3.7) | 356 (4.6) | 0.097 | 14 (6.7) | 95 (6.2) | 0.76 |
| Prior admission with dialysis, n (%) | 10 (0.1) | 18 (0.1) | 0.4 | 7 (0.4) | 27 (0.3) | 1.00 | 21 (10.0) | 195 (12.8) | 0.32 |
| Medication on admission | |||||||||
| Aspirin, n (%) | 2407 (25.4) | 8241 (34.3) | <0.001 | 933 (47.3) | 4561 (58.7) | <0.001 | 128 (61.2) | 1010 (67.0) | 0.1 |
| Clopidogrel, n (%) | 177 (1.9) | 1250 (5.2) | – | 61 (3.1) | 748 (9.6) | – | 12 (5.7) | 223 (14.8) | – |
| Ticagrelor, n (%) | 119 (1.3) | 0 (0.0) | – | 30 (1.5) | 6 (0.1) | – | 11 (5.3) | 5 (0.3) | – |
| Prasugrel, n (%) | 8 (0.1) | 0 (0.0) | – | 2 (0.1) | 1 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
| Warfarin, n (%) | 22 (0.2) | 228 (0.9) | – | 18 (0.9) | 150 (1.9) | – | 2 (1.0) | 27 (1.8) | – |
| NOAC, n (%) | 2 (0.0) | 3 (0.0) | – | 2 (0.1) | 1 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
| β-blocker , n (%) | 2303 (24.4) | 7509 (31.3) | <0.001 | 868 (44.2) | 4081 (52.8) | <0.001 | 136 (65.4) | 990 (66.1) | 0.88 |
| ACEI/ARB, n (%) | 1186 (15.1) | 2814 (14.9) | 0.71 | 453 (30.2) | 1578 (29.3) | 0.50 | 56 (35.9) | 373 (34.2) | 0.72 |
| Statin, n (%) | 2135 (22.5) | 6761 (28.1) | <0.001 | 693 (35.1) | 3102 (39.9) | <0.001 | 91 (43.5) | 730 (48.6) | 0.18 |
AF, atrial fibrillation; ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NOAC, novel oral anticoagulant; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI, ST-elevation myocardial infarction.